| pubmed-article:7556256 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7556256 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:7556256 | lifeskim:mentions | umls-concept:C0037303 | lld:lifeskim |
| pubmed-article:7556256 | lifeskim:mentions | umls-concept:C0021968 | lld:lifeskim |
| pubmed-article:7556256 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:7556256 | lifeskim:mentions | umls-concept:C0009924 | lld:lifeskim |
| pubmed-article:7556256 | lifeskim:mentions | umls-concept:C0296806 | lld:lifeskim |
| pubmed-article:7556256 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7556256 | pubmed:dateCreated | 1995-11-2 | lld:pubmed |
| pubmed-article:7556256 | pubmed:abstractText | In a single-centre comparative randomised double-blind trial, 40 patients undergoing head CT were examined using iobitridol and compared with 40 examined using iohexol. The contrast media were assessed for clinical safety and diagnostic efficacy. No significant difference was observed between the two groups and there were no significant reactions. It is concluded that iobitridol is a safe and effective contrast medium. | lld:pubmed |
| pubmed-article:7556256 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7556256 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7556256 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7556256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7556256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7556256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7556256 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7556256 | pubmed:month | May | lld:pubmed |
| pubmed-article:7556256 | pubmed:issn | 0720-048X | lld:pubmed |
| pubmed-article:7556256 | pubmed:author | pubmed-author:TaylorWW | lld:pubmed |
| pubmed-article:7556256 | pubmed:author | pubmed-author:MoseleyII | lld:pubmed |
| pubmed-article:7556256 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7556256 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:7556256 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7556256 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7556256 | pubmed:pagination | 57-60 | lld:pubmed |
| pubmed-article:7556256 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:meshHeading | pubmed-meshheading:7556256-... | lld:pubmed |
| pubmed-article:7556256 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7556256 | pubmed:articleTitle | Assessment of the safety and efficacy of iobitridol, an iodinated contrast medium (30% iodine), in cranial CT. | lld:pubmed |
| pubmed-article:7556256 | pubmed:affiliation | Lysholm Department of Radiology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. | lld:pubmed |
| pubmed-article:7556256 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7556256 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7556256 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7556256 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7556256 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
